Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Hexoprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 12/20 | 0.65 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.55 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.55 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.55 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MTOR | P42345 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexoprenaline SCHEMBL121449 | 0.94 | ADRB2 (0.72) | ADRB2ADRB1MAPTTDP1KDM4E | |
| Hexoprenaline SCHEMBL32668781 | 0.94 | ADRB2 (0.72) | ADRB2ADRB1MAPTTDP1KDM4E | |
| Hexoprenaline SCHEMBL1604446 | 0.92 | ADRB2 (0.70) | ADRB2ADRB1MAPTTDP1KDM4E | |
| Hexoprenaline SCHEMBL3500862 | 0.92 | ADRB2 (0.70) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL8442887 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL9768151 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL9768158 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL31530707 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL31530706 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1MAPTTDP1KDM4E | |
| SCHEMBL13790391 | 0.85 | ADRB2 (0.62) | ADRB2ADRB1MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-4801458-A | POROUS HOLLOW FIBERS FILLED WITH MEDICINE | TEIJIN LIMITED (JP) | 1989-01-31 | — | — | US | disclosed |
| US-4755544-A | Sustained release preparation | TEIJIN LIMITED (JP) | 1988-07-05 | — | — | US | disclosed |
| EP-0253901-A1 | SUSTAINED-RELEASE PREPARATION | TEIJIN LIMITED (JP) | 1988-01-27 | — | — | EP | disclosed |
| EP-0227836-A1 | SUSTAINED RELEASING PATCH | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0207638-A2 | Sustained-release pharmaceutical preparation | TEIJIN LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
| EP-0187703-A2 | Sustained release preparation | TEIJIN LIMITED (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | ADRB2 39/4885ADRB1 43/4885ADRB3 66/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | ADRB2 537/4885ADRB1 503/4885ADRB3 382/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ADRB2 2249/4885ADRB1 2529/4885ADRB3 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.